Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
35 participants
OBSERVATIONAL
2016-02-10
2021-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CytoSorb® in Patients With Acute on Chronic Liver Failure
NCT05131230
Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
NCT05413083
Renal Function Determination in Patients With Liver Cirrhosis
NCT02047240
Cytokine Adsorption in Acute-on-chronic Liver Failure
NCT05019352
Portal Pressure Effects of Phlebotomy Combined to Vasopressin Use in Cirrhotic Patients Undergoing Liver Transplantation
NCT04472312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
liver failure
patients diagnosed with acute liver failure or acute on chronic liver failure in accordance with national guidelines who require 3 consecutive sessions of hemoadsorption
hemoadsorption
three consecutive sessions of hemoadsorption in patients with liver failure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hemoadsorption
three consecutive sessions of hemoadsorption in patients with liver failure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* duration of therapy under 12 hours
* death before the three consecutive sessions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institutul Clinic Fundeni
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Popescu Mihai
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dana Tomescu, Prof
Role: STUDY_CHAIR
Fundeni Clinical Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundeni Clinical Institute
Bucharest, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cyto-ALF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.